{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:27:14Z","timestamp":1791581234142,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jmii.2021.01.001","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T15:39:20Z","timestamp":1610638760000},"page":"341-348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review"],"prefix":"10.1016","volume":"54","author":[{"given":"Chieh-Lin","family":"Jerry Teng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bor-Sheng","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jmii.2021.01.001_bib1","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"issue":"20","key":"10.1016\/j.jmii.2021.01.001_bib2","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jmii.2021.01.001_bib3","first-page":"103","article-title":"Complement-fixing antibodies against cytomegalovirus in different parts of the world","volume":"49","author":"Krech","year":"1973","journal-title":"Bull World Health Organ"},{"issue":"9","key":"10.1016\/j.jmii.2021.01.001_bib4","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1086\/508173","article-title":"Seroprevalence of cytomegalovirus infection in the United States, 1988-1994","volume":"43","author":"Staras","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.jmii.2021.01.001_bib5","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.jmii.2021.01.001_bib6","first-page":"603","article-title":"Seroprevalence of CMV antibodies in a blood donor population and premature neonates in the south-central Taiwan","volume":"15","author":"Lu","year":"1999","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jmii.2021.01.001_bib7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bbmt.2005.11.432","article-title":"Recurrent cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation in Taiwan: a single institutional experience","volume":"12","author":"Wu","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jmii.2021.01.001_bib8","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00277-011-1351-8","article-title":"Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus","volume":"91","author":"Liu","year":"2012","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.jmii.2021.01.001_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13096","article-title":"Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia","volume":"21","author":"Lin","year":"2019","journal-title":"Transpl Infect Dis"},{"issue":"7","key":"10.1016\/j.jmii.2021.01.001_bib10","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00277-019-03669-z","article-title":"The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT","volume":"98","author":"Schmidt-Hieber","year":"2019","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.jmii.2021.01.001_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12363","article-title":"Management of cytomegalovirus infection in haemopoietic stem cell transplantation","volume":"162","author":"Emery","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jmii.2021.01.001_bib12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol Oncol Clin N Am"},{"issue":"7","key":"10.1016\/j.jmii.2021.01.001_bib13","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","article-title":"CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia","volume":"122","author":"Green","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jmii.2021.01.001_bib14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/bjh.12875","article-title":"Relationship between cytomegalovirus (CMV) reactivation, CMV-driven immunity, overall immune recovery and graft-versus-leukaemia effect in children","volume":"166","author":"Jeljeli","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jmii.2021.01.001_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"3 Suppl 3","key":"10.1016\/j.jmii.2021.01.001_bib16","first-page":"13","article-title":"Haematopoietic stem cell transplantation in Taiwan: past, present, and future","volume":"15","author":"Chen","year":"2009","journal-title":"Hong Kong Med J"},{"issue":"2","key":"10.1016\/j.jmii.2021.01.001_bib17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4274\/tjh.2016.0225","article-title":"Cytomegalovirus infection and treatment in allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution in an endemic area","volume":"34","author":"Lin","year":"2017","journal-title":"Turk J Haematol"},{"issue":"2","key":"10.1016\/j.jmii.2021.01.001_bib18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1600-6143.2008.02513.x","article-title":"Interlaboratory comparison of cytomegalovirus viral load assays","volume":"9","author":"Pang","year":"2009","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.jmii.2021.01.001_bib19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.biologicals.2016.04.005","article-title":"A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology","volume":"44","author":"Fryer","year":"2016","journal-title":"Biologicals"},{"key":"10.1016\/j.jmii.2021.01.001_bib20","unstructured":"Roche Molecular System Inc. COBAS AmpliPrep\/COBAS Taqman CMV Test [package insert]. Taiwan Food and Drug Administration website. info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=56026713. Accessed Oct 08, 2014."},{"key":"10.1016\/j.jmii.2021.01.001_bib21","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1471-2334-7-138","article-title":"Relationship between pp65 antigenemia levels and real-time quantitative DNA PCR for Human Cytomegalovirus (HCMV) management in immunocompromised patients","volume":"7","author":"Cariani","year":"2007","journal-title":"BMC Infect Dis"},{"issue":"11","key":"10.1016\/j.jmii.2021.01.001_bib22","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.bbmt.2012.05.015","article-title":"Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation","volume":"18","author":"Green","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"10.1016\/j.jmii.2021.01.001_bib23","doi-asserted-by":"crossref","first-page":"5689","DOI":"10.1182\/blood-2011-06-361618","article-title":"Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients","volume":"118","author":"Milano","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jmii.2021.01.001_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-017-0180-z","article-title":"Who is the patient at risk of CMV recurrence: a review of the current scientific evidence with a focus on hematopoietic cell transplantation","volume":"7","author":"Styczynski","year":"2018","journal-title":"Infect Dis Ther"},{"issue":"4","key":"10.1016\/j.jmii.2021.01.001_bib25","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/TP.0b013e318224f263","article-title":"Immunological monitoring for guidance of preemptive antiviral therapy for active cytomegalovirus infection in allogeneic stem-cell transplant recipients: a pilot experience","volume":"92","author":"Solano","year":"2011","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.jmii.2021.01.001_bib26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jmii.2018.11.004","article-title":"Recommendations and guidelines for the treatment of pneumonia in Taiwan","volume":"52","author":"Chou","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"issue":"7","key":"10.1016\/j.jmii.2021.01.001_bib27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/14737159.2017.1325737","article-title":"Evaluation of COBAS AmpliPrep\/COBAS TaqMan CMV Test for use in hematopoietic stem cell transplant recipients","volume":"17","author":"Ramanan","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.jmii.2021.01.001_bib28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcv.2015.06.006","article-title":"Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients","volume":"69","author":"Tan","year":"2015","journal-title":"J Clin Virol"},{"issue":"7","key":"10.1016\/j.jmii.2021.01.001_bib29","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V95.7.2240","article-title":"Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation","volume":"95","author":"Broers","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jmii.2021.01.001_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014172","article-title":"Factors associated with cytomegalovirus infection in children undergoing allogeneic hematopoietic stem-cell transplantation","volume":"98","author":"Jaing","year":"2019","journal-title":"Medicine (Baltim)"},{"issue":"8","key":"10.1016\/j.jmii.2021.01.001_bib31","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood.V99.8.3050","article-title":"Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants","volume":"99","author":"Ljungman","year":"2002","journal-title":"Blood"},{"issue":"8900","key":"10.1016\/j.jmii.2021.01.001_bib32","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0140-6736(94)91835-X","article-title":"Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group","volume":"343","author":"Prentice","year":"1994","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jmii.2021.01.001_bib33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-118-3-199302010-00004","article-title":"Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial","volume":"118","author":"Winston","year":"1993","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.jmii.2021.01.001_bib34","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1182\/blood.V90.6.2502","article-title":"Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome","volume":"90","author":"Salzberger","year":"1997","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.jmii.2021.01.001_bib35","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jmii.2021.01.001_bib36","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/cid\/ciz490","article-title":"A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation","volume":"70","author":"Ljungman","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jmii.2021.01.001_bib37","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V88.10.4063.bloodjournal88104063","article-title":"Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study","volume":"88","author":"Boeckh","year":"1996","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jmii.2021.01.001_bib38","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.bmt.1705311","article-title":"Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients","volume":"37","author":"van der Heiden","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jmii.2021.01.001_bib39","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.V99.4.1159","article-title":"Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation","volume":"99","author":"Reusser","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jmii.2021.01.001_bib40","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1086\/383040","article-title":"A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients","volume":"189","author":"Mattes","year":"2004","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.jmii.2021.01.001_bib41","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1097\/00007890-200104150-00010","article-title":"Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation","volume":"71","author":"Platzbecker","year":"2001","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.jmii.2021.01.001_bib42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/tri.12225","article-title":"Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study","volume":"27","author":"Stoelben","year":"2014","journal-title":"Transpl Int"},{"issue":"4","key":"10.1016\/j.jmii.2021.01.001_bib43","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.V97.4.867","article-title":"Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes","volume":"97","author":"Nichols","year":"2001","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jmii.2021.01.001_bib44","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jmii.2021.01.001_bib45","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-109-10-777","article-title":"Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin","volume":"109","author":"Emanuel","year":"1988","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.jmii.2021.01.001_bib46","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2165\/00003495-199448030-00009","article-title":"Ganciclovir. An update of its therapeutic use in cytomegalovirus infection","volume":"48","author":"Markham","year":"1994","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.jmii.2021.01.001_bib47","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00277-019-03755-2","article-title":"Age-dependent determinants of infectious complications profile in children and adults after hematopoietic cell transplantation: lesson from the nationwide study","volume":"98","author":"Czyzewski","year":"2019","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.jmii.2021.01.001_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228451","article-title":"Viral reactivations following hematopoietic stem cell transplantation in pediatric patients - a single center 11-year analysis","volume":"15","author":"Duver","year":"2020","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.jmii.2021.01.001_bib49","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/tid.12539","article-title":"Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation","volume":"18","author":"Ju","year":"2016","journal-title":"Transpl Infect Dis"},{"issue":"11","key":"10.1016\/j.jmii.2021.01.001_bib50","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.bbmt.2015.07.019","volume":"21","author":"Takenaka","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jmii.2021.01.001_bib51","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.bbmt.2020.01.027","article-title":"Letermovir for secondary prophylaxis of cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the French compassionate program","volume":"26","author":"Robin","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jmii.2021.01.001_bib52","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00007890-199608150-00013","article-title":"Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation","volume":"62","author":"Bacigalupo","year":"1996","journal-title":"Transplantation"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118221000141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118221000141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:26:11Z","timestamp":1761657971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118221000141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1684118221000141"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2021.01.001","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2021.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}